HLA-C and renal cell carcinoma: Finally, precision immunotherapy targeting surface antigens with chimeric antigen receptor (CAR) T cells and MHC antigens with tumor infiltrating lymphocytes (TILs) are under early development in RCC (NCT02830724, NCT03393936, and NCT03638206) [161].